Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Harvoni Cost Will Be Roughly Equal To Sovaldi For Most HCV Patients (Updated)

This article was originally published in The Pink Sheet Daily

Executive Summary

Sovaldi/ledipasvir combo pill – the first one-tablet, oral hepatitis C option in the U.S. – was approved Oct. 10 with a price of $94,500 for a 12-week course of therapy, similar to the cost of Sovaldi plus interferon and ribavirin. Insurers group says Gilead “seems to believe it has a blank check.”

You may also be interested in...

Sovaldi: Shooting Star Rather Than Blockbuster?

Gilead’s hepatitis C virus (HCV) treatment has earned a special place in pharma lore with its rapid rise to about $10 billion in annual sales, bringing with it lots of controversy about the sustainability of specialty drug pricing. Now the product appears poised to make a new reputation: fastest to fall from blockbuster status.

Gilead Gets Positive EU Opinion On Proprietary HCV Combo Pill Harvoni

Europe’s top scientific advisory panel has cleared for approval Gilead’s new hepatitis C antiviral combination of sofosbuvir plus ledipasvir, as well as Almirall’s new inhaled combo of aclidinium and formoterol and AstraZeneca’s new constipation therapy naloxegol.

Pulling In 10 Different Directions – The Challenge Of Harmonizing Asia’s VMS Market

A lack of regulatory harmonization for dietary supplements in Asia is a big challenge facing companies operating in the region, according to experts from the Asia Regulatory Professionals Association. The ARPA is looking to start a conversation on the issue which the association hopes will lead to regulatory change.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts